Hancock Jaffe Laboratories to Present at The MicroCap Conference on October 2, 2018 in New York City
September 28 2018 - 6:00AM
Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company
specializing in medical devices that restore cardiac and vascular
health, today announced that it will present and meet with
potential investors at The MicroCap Conference on October 1 and 2
at The Essex House in New York City. HJLI’s presentation will take
place at 10:00 am EDT on Tuesday, October 2. Interested
investors should register for the conference at
www.microcapconf.com, or should contact the company directly to
request a meeting.
HJLI is currently waiting for approval from
INVIMA, the Colombian equivalent of the US FDA, to begin its
first-in-human trial for the Company’s VenoValve®, a medical device
designed to treat severe cases of Chronic Venous Insufficiency
(“CVI”). Severe CVI occurs when valves in the deep venous
system of the leg malfunction, causing blood to pool in the lower
extremities. Severe CVI includes swelling, debilitating pain, and
skin ulcerations that become ongoing, open wounds. Approximately
4.5 million people in the U.S. suffer from severe CVI and the U.S.
economic burden of venous ulcers from CVI has been estimated to be
as high as $38 Billion a year. There are currently no FDA approved
treatments for severe CVI.
About Hancock Jaffe Laboratories, Inc.
HJLI specializes in developing and manufacturing
bioprosthetic medical devices to establish improved standards of
care for treating cardiac and vascular diseases. HJLI currently has
three product candidates: the porcine tissue based VenoValve®,
which is intended to be surgically implanted in the deep venous
system of the leg to treat Chronic Venue Insufficiency; the
CoreoGraft®, a bovine tissue based off the shelf conduit intended
to be used for coronary artery bypass surgery, and a porcine tissue
based heart valve, which based upon its relatively small size and
increased output, is an ideal candidate for pediatric aortic/mitral
valve replacement.
Cautionary Note on Forward-Looking
Statements
This press release and any statements of
stockholders, directors, employees, representatives and partners of
Hancock Jaffe Laboratories, Inc. (the “Company”) related thereto
contain, or may contain, among other things, certain
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Such
forward-looking statements involve significant risks and
uncertainties. Such statements may include, without
limitation, statements identified by words such as "projects,"
"may," "will," "could," "would," "should," "believes," "expects,"
"anticipates," "estimates," "intends," "plans," "potential" or
similar expressions. These statements are based upon the
current beliefs and expectations of the Company’s management and
are subject to significant risks and uncertainties, including those
detailed in the Company’s filings with the Securities and Exchange
Commission. Actual results (including, without limitation,
the performance of the new board members described herein) may
differ significantly from those set forth or implied in the
forward-looking statements. These forward-looking statements
involve certain risks and uncertainties that are subject to change
based on various factors (many of which are beyond the Company’s
control). The Company undertakes no obligation to publicly
update any forward-looking statements, whether as a result of new
information, future presentations or otherwise, except as required
by applicable law.
HJLI Press Contacts:
Amy Carmer Tel: 949-261-2900 Email: ACarmer@HancockJaffe.com
Jules Abraham CoreIRTel: 917-885-7378Email:
julesa@coreir.com
Hancock Jaffe Laboratories (NASDAQ:HJLIW)
Historical Stock Chart
From Aug 2024 to Sep 2024
Hancock Jaffe Laboratories (NASDAQ:HJLIW)
Historical Stock Chart
From Sep 2023 to Sep 2024